|Bid||45.31 x 800|
|Ask||45.32 x 1100|
|Day's range||44.95 - 45.38|
|52-week range||44.30 - 63.69|
|Beta (3Y monthly)||0.87|
|PE ratio (TTM)||15.05|
|Earnings date||25 Apr 2019|
|Forward dividend & yield||1.64 (3.44%)|
|1y target est||57.80|
Investors are looking forward to Revlimid's performance and updates on the impending acquisition agreement with Bristol-Myers, when Celgene Corporation (CELG) reports Q1 results.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
Bristol-Myers (BMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.
Performance of Opdivo and the impending acquisition of Celgene Corporation will be key areas of focus for the investors, when Bristol-Myers (BMY) reports first-quarter results.
These two marijuana stocks reported very different results last quarter. Plus, how Abbott's challenging Dexcom in diabetes, and what's next for Bristol-Myers following its Celgene acquisition.
Bristol-Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Looking at Bristol-Myers Squibb Company's (NYSE:BMY) earnings update in December 2018, analyst consensus outlook appear cautiously optimistic, with earnings expected to grow by...
Bristol-Myers Squibb Company announced today the commencement, in connection with its previously announced acquisition of Celgene Corporation , of an exchange offer for any and all outstanding notes issued by Celgene for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb and cash.
In the latest trading session, Bristol-Myers Squibb (BMY) closed at $46.02, marking a -1.03% move from the previous day.
The fat lady is getting ready to sing with this big pharma deal. Celgene shareholders will soon have a decision to make.
Clovis Oncology (CLVS) halts mid-stage bladder cancer study evaluating Rubraca monotherapy. It is unlikely to provide meaningful clinical benefit as reviewed by an independent data monitoring committee.
By Michael Erman and Svea Herbst-Bayliss NEW YORK (Reuters) - Bristol-Myers Squibb Co's shareholders voted to approve the drugmaker's $74 billion (56.6 billion pounds) acquisition of biotech Celgene Corp ...
The deal, announced in January, was a hard sell to Bristol shareholders from the start. The approval concludes a tumultuous period for Bristol, which saw pushback from institutional investors.
Bristol-Myers Squibb Company (BMY) today announced that its shareholders voted to approve the issuance of shares of Bristol-Myers Squibb common stock in connection with the Company’s pending merger with Celgene Corporation (CELG) at the Special Meeting of Stockholders. “We are pleased with the outcome of today’s Special Meeting and thank our shareholders for their support for this combination,” said Giovanni Caforio, M.D., Chairman and Chief Executive Officer of Bristol-Myers Squibb. “Together with Celgene, we will create a premier innovative biopharma company with leading scientific capabilities that is well positioned to address the needs of patients through high-value innovative medicines.
Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.
Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. The drug's label expansion programs also appear encouraging.
The U.S. Environmental Protection Agency (EPA) has recognized Bristol-Myers Squibb Company (BMY) with an ENERGY STAR® Partner of the Year Sustained Excellence Award for its outstanding contributions and leadership to improve the energy efficiency of facilities worldwide. Bristol-Myers Squibb has earned the ENERGY STAR® Partner of the Year award for the past five consecutive years. “We are proud to have our commitment to environmental responsibility recognized with the ENERGY STAR Partner of the Year Sustained Excellence Award,” said Carol Ryerkerk Powell, vice president of Environment, Health, Safety and Sustainability, Bristol-Myers Squibb.
Columbia fund manager David King also likes a group of convertible preferred-stock issues, which offer higher yields than common shares.
Bristol-Myers Squibb (BMY) closed the most recent trading day at $45.98, moving -1.73% from the previous trading session.